Moderna (NASDAQ:MRNA) Price Target Cut to $111.00 by Analysts at Barclays

Moderna (NASDAQ:MRNA) had its price target reduced by Barclays from $125.00 to $111.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. The Goldman Sachs Group dropped their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. JPMorgan Chase & Co. dropped their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Piper Sandler dropped their price objective on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $93.18.

Moderna Price Performance

Moderna stock traded down $3.45 during midday trading on Friday, hitting $46.83. 13,561,538 shares of the company’s stock were exchanged, compared to its average volume of 4,882,079. The stock has a 50-day moving average price of $61.85 and a two-hundred day moving average price of $99.22. Moderna has a 52-week low of $46.57 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The company has a market cap of $18.00 billion, a P/E ratio of -3.04 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the prior year, the business earned ($1.39) EPS. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities research analysts forecast that Moderna will post -9.89 earnings per share for the current year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock valued at $238,531 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several large investors have recently made changes to their positions in MRNA. Vontobel Holding Ltd. lifted its position in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after buying an additional 69,313 shares in the last quarter. Profund Advisors LLC lifted its holdings in Moderna by 20.9% during the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after buying an additional 9,719 shares during the period. Tobam lifted its holdings in shares of Moderna by 121.6% during the 3rd quarter. Tobam now owns 27,794 shares of the company’s stock valued at $1,857,000 after purchasing an additional 15,249 shares during the last quarter. Swedbank AB lifted its holdings in shares of Moderna by 149.6% during the 3rd quarter. Swedbank AB now owns 85,099 shares of the company’s stock valued at $5,687,000 after purchasing an additional 51,000 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Moderna by 295.5% in the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock valued at $4,180,000 after acquiring an additional 26,300 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.